Airoha Technologies announces ISM6331 clinical data
The story so far
InsiTech announced preliminary positive data from the first human Phase I clinical trial of its investigational oral pan-TEAD inhibitor ISM6331. As of August 14, 2026, the once-daily 130mg dose group achieved an objective response rate (ORR) of 40%, and the disease control rate (DCR) in the 30-130mg dose range was 68.2%. The data was presented at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting.
AI-written from the reports · Updated 23 days ago
Coverage timeline
Follow the coverage to see every side of the story.
- 36Kr · AIInsilico Therapeutics announced preliminary positive data from the first human Phase I clinical trial of ISM6331
Insilico Therapeutics released Phase I clinical data of the investigational oral pan-TEAD inhibitor ISM6331 at the ESMO Annual Meeting. As of August 14, 2026, the once-daily 130mg dose group achieved an objective response rate (ORR) of 40%, and the disease control rate (DCR) in the 30-130mg dose range was 68.2%.